Jun 02, 2022 / 06:00PM GMT
Phil Nadeau - Cowen and Company, LLC - Analyst
Good afternoon, and welcome once again to Cowen & Company's Third Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to moderate our fireside chat with Atreca. We have with us this afternoon, John Orwin, the Chief Executive Officer; Herb Cross, Chief Financial Officer; Tito Serafini, Chief Strategy Officer; Jonathan Benjamin, the SVP of Clinical Research. I believe Alex Gray from Investor Relations is also in the room.
Questions and Answers:
Phil Nadeau - Cowen and Company, LLC - AnalystJohn, maybe we'll start with you. Last time, you announced a corporate restructuring to extend your cash runway. Could you discuss how you have prioritized your spend and the impact that's going to have on your operational runway?
John Orwin - Atreca, Inc. - President & CEO
Yeah, thanks for the question, Phil. I think we found ourselves in a position where we have seen responses for ATRC-101, our clinical-stage
Trustpilot
